Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass PathwaysCMPS +0.46%32 EV-to-EBITDA is -5.99 as of Jul. 30, 2026. GuruFocus rates CMPS with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 509 Healthcare Providers & Services companies, Compass Pathways ranks worse than 196463.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Compass Pathways's enterprise value is $1,058.24 Mil.
Compass Pathways's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-176.60 Mil. Therefore, Compass Pathways's EV-to-EBITDA for today is -5.99.
The historical rank and industry rank for Compass Pathways's EV-to-EBITDA or its related term are showing as below:
CMPS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.18 Med: 0 Max: 0
Current: -5.99
CMPS's EV-to-EBITDA is ranked worse than 100% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.14
vs CMPS: -5.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Compass Pathways's PE Ratio (TTM) for today is calculated as:
Compass Pathways's share price for today is $10.91.
Compass Pathways's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Compass Pathways's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Compass Pathways's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Compass Pathways's EV-to-EBITDA falls into.
Compass Pathways's current Enterprise Value is $1,058.24 Mil.
Compass Pathways's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-176.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (CMPS) has a EV-to-EBITDA of -5.99 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compass Pathways. According to the industry distribution chart, Compass Pathways ranks #999999 out of 509 companies in the Healthcare Providers & Services industry.
Is Compass Pathways' EV-to-EBITDA too high?
Compass Pathways' current EV-to-EBITDA is -5.99. Based on the distribution chart, Compass Pathways ranks #999999 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Compass Pathways has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' EV-to-EBITDA compare to ARDT and HCSG?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #999999 out of 509 companies for EV-to-EBITDA. This places Compass Pathways in the lower half of its industry. The industry median EV-to-EBITDA is 11.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.14, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compass Pathways. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Pathways's current EV-to-EBITDA is -5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current EV-to-EBITDA of -5.99. The current EV-to-EBITDA is -5.99. Compass Pathways' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Compass Pathways (CMPS), the current EV-to-EBITDA is -5.99 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
32GF Score
Get the complete analysis for CMPS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPS has been successfully added to your 
